Dasatinib sensitizes primary chronic lymphocytic leukaemia  lymphocytes to chlorambucil and fludarabine in vitro.
The dual c-abl/Src kinase inhibitor, dasatinib, utilized to treat chronic myeloid leukaemia (CML) when used at clinically attainable sublethal concentrations, synergistically sensitized primary chronic lymphocytic leukaemia (CLL) lymphocytes to chlorambucil and fludarabine. In contrast, dasatinib alone demonstrated toxicity to CLL lymphocytes at concentrations that are generally not clinically attainable. Dasatinib resistance and poorer dasatinib-mediated sensitization to chlorambucil and fludarabine was associated with higher expression of c-abl protein levels. In contrast, chlorambucil and fludarabine resistance correlated with basal p53 protein levels. Moreover, Western blot analysis after in vitro treatment of primary CLL lymphocytes with dasatinib, chlorambucil and/or fludarabine, showed that dasatinib: (i) inhibited c-abl function (e.g. downregulation of c-abl protein levels and decreased the phosphorylation of a c-abl downstream target, Dok2), (ii) decreased chlorambucil/fludarabine induced accumulation of p53 protein levels, (iii) altered the response to chlorambucil/fludarabine induced DNA-damage as evidenced by an increase in chlorambucil/fludarabine-induced H2AX phosphorylation, and (iv) accentuated the c-abl downregulation induced by chlorambucil/fludarabine. Our results suggest that dasatinib in combination with chlorambucil or fludarabine may improve the therapy of CLL.
Amrein
Lilian
L
Lady Davis Institute for Medical Research-Cancer Segal Center, Sir MB Davis-Jewish General Hospital, Montreal, Canada
Hernandez
Tiffany A
TA
Ferrario
Cristiano
C
Johnston
James
J
Gibson
Spencer B
SB
Panasci
Lawrence
L
Aloyz
Raquel
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015153:Blotting, Western / Q000379:methods; D002470:Cell Survival; D002699:Chlorambucil / Q000008:administration & dosage; D003601:Cytotoxicity Tests, Immunologic; D004252:DNA Mutational Analysis; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004357:Drug Synergism; D006801:Humans; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D016014:Linear Models; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D016315:Proto-Oncogene Proteins c-abl / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*; D018709:Statistics, Nonparametric; D013844:Thiazoles / Q000627:therapeutic use*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D016159:Tumor Suppressor Protein p53; D002699:Chlorambucil; D016315:Proto-Oncogene Proteins c-abl; D014740:Vidarabine; C024352:fludarabine; D000069439:Dasatinib